The treatment of tumor explants from ERα-positive/ERβ-negative-HGSOC-patient-derived xenografts (PDXs) with either 4-hydroxytamoxifen or fulvestrant has also provided support for the idea of ERα mediating the effects of these drugs [70]. This evidence concerns the gene ESR2 and neoplasm.